OPKO Health, Inc. (NASDAQ:OPK) Receives $1.55 Consensus Target Price from Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received an average recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $1.55.

Several equities research analysts recently commented on the stock. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings downgraded shares of OPKO Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th.

OPKO Health Stock Down 1.8%

NASDAQ:OPK opened at $1.10 on Wednesday. The firm’s 50 day simple moving average is $1.17 and its 200 day simple moving average is $1.26. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. OPKO Health has a one year low of $0.98 and a one year high of $1.60. The company has a market cap of $830.60 million, a PE ratio of -4.07 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The business had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. During the same period last year, the company earned ($0.10) EPS. The firm’s revenue was down 17.1% compared to the same quarter last year. On average, research analysts anticipate that OPKO Health will post -0.29 earnings per share for the current year.

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. Caprock Group LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $26,000. Zacks Investment Management acquired a new position in shares of OPKO Health in the 4th quarter worth approximately $27,000. StoneX Group Inc. acquired a new position in shares of OPKO Health in the 4th quarter worth approximately $27,000. Swiss Life Asset Management Ltd acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $30,000. Finally, Savant Capital LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $33,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.